All right. Hi, everyone. Greetings from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the Senior Large-Cap Biotech Analyst. It's my pleasure to introduce our next company, Seagen, almost called you Seattle Genetics, and Chairman and CEO Clay Siegall. Please note that following Clay's presentation, we will have a Q&A session right here in this Zoom room where you're able to submit your questions via the little blue Ask a Question button in your conference portal. With that, Clay, thanks for being here today. Let me turn things over to you. Thanks, Cory, for the introduction. I'm delighted to be here at the virtual JPMorgan Healthcare Conference. Before I start my presentation, I want to mention that I will be making forward-looking statements, so please refer to our SEC filings for more information. Next slide. Okay. I want to start by talking about the key accomplishments for 2021, and these accomplishments are basically focused on our three products, ADCETRIS, PADCEV, and TUKYSA. First of all, with ADCETRIS, we received a number of additional ex-U.S. approvals, and that's with our collaborator, Takeda, including and importantly, China. We also have put out five-year PFS data, which was extraordinary with ECHELON-1 and also with ECHELON-2, based on our phase III trials. The follow-up from that has been very positive, and I'll discuss that briefly. With PADCEV, our second drug that was approved, we, in frontline, had breakthrough designation in urothelial carcinoma, in combination with KEYTRUDA. We have significantly improved OS in a phase III trial that we have reported top-line data, but that will be coming ASCO GU shortly. We also have another set of data coming out at ASCO GU on the positive data for a cis-ineligible pivotal trial cohort. We're really excited about what we're doing and where we're going on all those fronts. With TUKYSA, we are approved in the U.S., Australia, and a couple other countries through Project Orbis, and that's something that we are going to be building on. We have a positive EU CHMP opinion. That is something that we are working hard to try to get approval across Europe. We have a collaboration with Merck, and this is on ex-U.S. and ex-Europe and ex-Canada. It mainly focuses on Asia, Middle East, and LATAM. We're delighted to work with Merck on TUKYSA. When you look at our pipeline programs, we have a number of late-stage programs and early-stage. I'll be mentioning 14 different programs, most of them in brief due to time. We have positive tisotumab vedotin data that is leading to a pivotal trial results that were great, and we plan on submitting that shortly. We have LV, ladiratuzumab vedotin, which is now being prosecuted globally at a 50/50 deal with Merck. Quite a number of exciting IND submissions and early-stage programs that are in phase I or headed to phase II. Next slide, please. This is now slide four. Seagen is very well-positioned from a global standpoint, and we have three main focuses. One will be to maximize the global potential of our three approved products. The second thing is to advance our late-stage programs, and that's something we're working really hard on. Last, it's expanding the early-stage pipeline. That's going to be the bulk of my talk, is really focusing on these three programs. Next slide. I'm going to start with talking about maximizing the global potential. That's of the three approved products. Next slide. Now we are on slide six. The three products are ADCETRIS, PADCEV, TUKYSA. I mentioned these. These are all either first-in-class or best-in-class products, and that's really what Seagen has mainly been working on, and products that can really impact patients. Okay. Next slide seven. We had a record year in product sales, a record year. In the third quarter, record numbers driven by our diverse commercial portfolio. First of all, we have been maintaining our ADCETRIS first-line market shares. This is despite the challenges of COVID-19, where we had lower diagnosis than what we've seen historically with Hodgkin lymphoma. The shift of care, differently than non-COVID setting, is negatively affecting our gross-to-net pricing. Despite those winds that we're facing, we have maintained market share with ADCETRIS. In addition, PADCEV has shown rapid adoption of growth, both in academic and community settings. TUKYSA has shown a great first quarter of sales. The uptake really is attributed to a very strong placement in guidelines and inclusion in pathways, and a strong following amongst the key doctors and patient advocacy groups. With TUKYSA, we are treating patients, and it's used and prescribed for patients with visceral disease and with those with brain mets. Next slide. Slide eight. On ADCETRIS. This is an expanding global brand. It's approved in the U.S., it's approved in Canada for six indications in Hodgkin lymphoma and peripheral T-cell lymphoma, including in the frontline setting. We focus on our commercial sales in the U.S. and Canada. Our partner, Takeda, commercialize it in the rest of the globe. We are continued to, even though ADCETRIS has been out for 10 years and has six labels, we're continuing to work with multiple trials, in Hodgkin lymphoma and other CD30-expressing lymphomas to try to increase the number of labels we have. Next slide. I wanted to touch on something I mentioned, which is the five-year durability of ECHELON-1 in Hodgkin lymphoma. This is a critical milestone. Doctors call the five-year data the gold standard, and they want to see what happens there. In this case, we have been treating Hodgkin lymphoma patients, which had the same therapy for decades. Showing one year, two years, three years is very nice, but showing five years is really important to doctors. The data continue to demonstrate the durability of the benefit. You could see the Kaplan-Meier lines being, at this point, really flat. What's important to know is that the PFS at five years looks very strong in both Stage III and Stage IV patients with Hodgkin lymphoma. You may recall that when we first put out the data, we had two years' worth of data, and we did not have a large number of events in Stage III, so it was hard to really know for sure. At this point, we have a lot of events in both Stage III and IV, and you could see the hazard ratios are strong and even better in Stage III. Additional findings that are really important are at this five-year time point for ADCETRIS plus AVD are that we have fewer secondary malignancies and a higher number of pregnancies in ADCETRIS AVD. That's largely because of the more intensive therapy you need when you get ABVD and other therapies such as transplant that you don't need if you get ADCETRIS AVD. That's a really important finding that we now know at five years. Also the peripheral neuropathy, which is in the label and is a known side effect of ADCETRIS. We've shown over time and over five years it improves or resolves very well. We feel that this is the right thing for patients with Stage III or IV Hodgkin lymphoma, and they really should consider this as standard of care. Next slide is slide 10. Now we want to maximize the potential of ADCETRIS, and that's across any way we can do it in patients that can respond to ADCETRIS. First of all, in Hodgkin lymphoma, I just want to highlight, rather than talk about everything, highlight the frontline approach in all patients. We have a Stage I, II, and a Stage III, IV approach, and this is ADCETRIS plus Opdivo plus AD. In this case, we're dropping out the V. Initially, we dropped out bleomycin, which was very lung toxic. By dropping out vinblastine, we now can get less neurotoxicity. The initial data we've seen with ADCETRIS, Opdivo from AD is spectacular. We're doing a lot more work on that, not only in the late stage but also in the early stages to try to say, even in the early stage, could we get rid of some of the chemotherapy that's the most toxic of the components? When you look at CD30 expressing NHL, we are looking a lot at frontline patients. One thing I'll call out is the frontline PTCL in patients that have less than 10% CD30 expression based on histology, which is a blunt tool and is not an accurate tool to say no CD30 or yes CD30. It's really a gray line, and we know from a lot of work we've done that if you're less than 10% CD30, you still respond well. CD30 is an activation antigen. The expression goes up and down, and in different tissue sections, it could be higher or lower. It's really important to do the work so that we don't exclude patients that could really benefit from frontline PTCL therapy with ADCETRIS. Then we're doing a variety of exploratory trials, especially in refractive solid tumors with ADCETRIS plus KEYTRUDA, based on some initial interesting observations here related to T-regulatory cells. More on that later. Next slide is slide 11. I'm going to switch to PADCEV. PADCEV is a very exciting product. It is something that's approved now to treat urothelial carcinoma. It targets Nectin-4, which is expressed in very high density in urothelial carcinoma. It does not need a screen. The FDA approved this right at the end of 2019. It was in mid-December for previously untreated urothelial cancer, largely bladder cancer that has metastasized. There is a lot of opportunities here in combination with KEYTRUDA, and we're working very hard on this product with our collaborators at Astellas. The next slide, which is slide 12 on my screen. PADCEV has been shown to induce high response rates. We've shown this previously in EV-201. That was what was presented. We have approval there, and it's in the setting where you have patients have received a platinum and a PD or PD-L1. In that setting, we had the best response rate with very strong duration that you could see. A 44% response rate with a duration of about seven and a half months. We were approved based on this in this setting where patients have had two prior therapies. We've come out with data that we've shown top-line data for two more trials. Both of these full data sets will be presented at ASCO GU coming up in the near future. The first of them is the EV-201 cohort 2. These were in patients that weren't eligible to receive cisplatin. They were unlike cohort 1. These patients are generally frail and brittle, and really have a tough time getting therapy. We found an ORR of 52% with duration of almost 11 months. You could look at cohort two and think about it and call it more like second-line therapy, which is cohort one is more like third-line therapy. What's really important to know here is that we have a better response rate with longer duration in second-line than in third-line. We're excited to show the full data at ASCO GU. The other trial was the EV-301 trial, and that's in 600 patients. That's much like EV-201, that's post-platinum and PD-1, but this is in a randomized setting versus chemotherapy. What we saw was we hit statistically meaningful OS and PFS. Because of that, the IDMC recommended at an interim analysis to stop the study for efficacy because we were already in very good shape here. We're going to be presenting the full data at ASCO GU coming up shortly. We are planning supplemental BLAs to get labels for cohort 2 and label for EV-301. The 301 label not only is just in the U.S., but that will also be for international submissions that we plan in the first half of this year. Now with the FDA, we plan our submissions this quarter. Expect those sometime in the not-too-distant future. Next slide, which is slide 13. The last thing I wanted to talk about with PADCEV was how well this works with KEYTRUDA, and we think this could support registration trials in frontline metastatic urothelial cancer. When you combine PADCEV and KEYTRUDA, you have 93% of patients have tumor reduction and 73% have an objective response with very strong PFS and OS. Our OS data wasn't even reached at 12 months. We're very excited about our frontline opportunity here and the continued trials. The next slide shows you the two potential opportunities we have for approval in frontline, or first line, I should say. One is what we call cohort K from the EV-103 study, and this is an accelerated pathway that we worked on in connection with regulators in the U.S. to enroll 150 patients, half of them with PADCEV alone and half with PADCEV plus KEYTRUDA, with the primary endpoint being objective response rate supported by the duration of response. Today is the first time we'll say that we will complete this enrollment of this trial before the end of 2021. We're excited to do it. We're excited with our ongoing enrollment. Getting this complete will then lead us to a point where we can then follow- up for duration of response like one does normally after filling out the enrollment of the protocol. The second trial is a randomized phase III trial we call EV-302, and that's PADCEV plus KEYTRUDA versus a chemo doublet of platinum plus Gemzar. This is enrolling 760 patients. It doesn't matter if you're eligible for platinum or not. It doesn't matter what your expression of PD-1 is. This type of trial would lead to a very simple way to diagnose and treat patients with PADCEV and KEYTRUDA in front line. It has dual primary endpoints of PFS and OS. Both of these study, one the accelerated and one the global trial, are underway and doing very well. Next slide on slide 15. This shows you the broad array of what we're doing with PADCEV across urothelial cancer. First of all, in the first column, we have an approved EV-201 trial. We're selling to that. Second of all, and third, we'll be submitting our 201 cohort 2 and the EV-301 randomized trial. Those should be submitted in the first quarter or second quarter, depending on whether it's just in U.S. or global. The combinations with KEYTRUDA. I've talked about how cohort K, we should complete enrollment this year. That's enrolling now. EV-302 enrolling now. We also have two other trials that I haven't mentioned in this talk yet. One is in muscle invasive bladder cancer. Actually, we have a couple of trials that we're doing in combination with Merck in muscle invasive bladder cancer in combination with KEYTRUDA. These are in patients that are cis-ineligible and cis-eligible, and they're enrolling. Lastly, in urothelial carcinoma, we will be exploring monotherapy in non-muscle invasive disease. That's the earliest stage of disease where it is just focused on the vesicle or the bladder. The trial is planned for intravesicular administration in patients that are not responsive to BCG. That should start sometime soon. Next slide 16, focuses on TUKYSA. TUKYSA is our third approved drug, and TUKYSA is a drug that is a best-in-class small molecule inhibitor of tyrosine kinase that targets HER2. This was approved in April of 2020 in combination with a few other chemotherapy agents for the treatment of metastatic HER2-positive breast cancer, and we are right now working to get this around the globe. We're approved in four additional countries. We had a positive CHMP opinion. We were recently granted a PIMS, or Promising Innovative Medicine Designation, in the U.K. That's something that we're very proud of. We are collaborating with Merck to commercialize TUKYSA outside of the U.S., Canada, and Europe. Our European team is set, it's in full force, and we're really looking forward to getting this drug commercialized all across Europe. The next slide 17, shows you one aspect of data that we haven't talked about that much, but it's the promising data we have with TUKYSA plus the standard of care, KADCYLA, that's used in first line. This is a trial in first line and second line HER2-positive metastatic breast cancer. KADCYLA is used regularly, and we think they could be used very well together and attack the inside of the cell with TUKYSA and the outside of the cell with KADCYLA. We have demonstrated that this combination is safe and it's active, including in patients with measurable and active brain metastasis. You can see from the chart that we have an ORR of 47% in patients with measurable disease and 36% in patients that have brain metastasis. You can see in the right side, we have a waterfall chart showing the change in the sum of the lesions in the brain mets. We really have an impact on brain mets, and I think that's what differentiates this combination approach. We are involved in doing this study right now, and it's enrolling. The next slide 18, shows you the broad TUKYSA development program that encompasses what we're doing not only in breast cancer, but in GI cancers. In breast cancer, we're already approved with a HER2CLIMB trial, in patients that have one or more positive HER2 therapeutic regimens in the metastatic setting. We're already enrolling in HER2CLIMB-0 2. That's the trial that's in metastatic breast cancer, and you have to have prior taxane and trastuzumab, and that's in combination with KADCYLA, as I mentioned. We're also working on advancing into early-stage breast cancer through the COMPASS trial in the adjuvant high risk of relapse setting. That's enrolling. In GI cancers, we have expanded into colorectal carcinoma. We've already presented very strong data in combination with trastuzumab and colorectal cancer. Right now we are trying to complete enrollment of the MOUNTAINEER study, which is a phase II pivotal trial. We intend to complete enrollment by the end of the year. That's another drug that hopefully the data turn out just like what we saw in our lead-in trial. We'd be able to get another approval in that regard. We're also pursuing gastric cancer now in a MOUNTAINEER-02 trial. That is enrolling. We're also doing a basket trial and exploring other solid tumors that are HER2- positive and HER2 mutant, which is important as many tumors are that, and that's enrolling as well. The next section really just focuses on our advanced late-stage programs, I'll touch on very briefly. Tisotumab vedotin is a drug that we are planning to submit BLA in the first quarter of this year. This is an ADC targeting tissue factor. We do this in collaboration with Genmab, it's for patients with cervical cancer. Historically, metastatic cervical cancer has not been treated well. There's this very limited opportunity for these patients, that's where TV comes in. Our data that we put out from innovaTV 204 shows meaningful and durable responses, with TV in these patients that really have no other option to be treated. We think that TV is positioned to be our fourth commercial product. The next slide 21, shows you where we are with ladiratuzumab vedotin or LV. That's really an emerging late-stage program that we hope to get into pivotal trials, whether it be single agent or combination agent, this year. That's our goal for this year. We're working with Merck on this in a 50/50 global collaboration. This is an ADC that targets LIV-1, that's broadly expressed in breast cancer and some other solid tumors. Our data as single agent are very encouraging, showing dozens of responses. In combination with KEYTRUDA, we also have very strong data in triple-negative breast cancer. We're really focused on optimizing the dose and schedule and patient populations and look forward to when we could put this into pivotal trials. The next slide talks briefly about our early-stage pipeline. This is slide 22. I'll go right to slide 23. We have five different ADCs that we're developing clinically and four different non-ADCs. These are empowered antibodies using our SEA technology. We are really excited about all of these products and look forward to presenting data on our ADCs. These all use auristatin-type payloads and some novel drug linkers in addition to the drug linkers that are involved in ADCETRIS and PADCEV. We continue to innovate on our drug linker front. We are excited with our work on the SEA technology, where we have enhanced engagement of the activating Fc gamma receptor. This is something that you'll hear a lot more about with more data later this year. Lastly, we have a strong financial position, which fuels the company's future. We had in the nine months ending September 20th, 2020, we had total revenues of $1.6 billion. That includes product sales in the U.S., royalty, and our collaboration revenues. What you could see is our total revenues on the right side continues to grow, and our products continue to grow. We're very pleased with how we are situated financially, and we have no debt. I think this is my last slide, is the milestones and growth catalyst for 2021 really abound. We're looking at the three major units that I talked about, maximizing the global potential of our three products. They're in 10 registrational studies. We'll report results at ASCO GU. We'll be submitting more for approval and completing enrollment in frontline with PADCEV, and in a pivotal study with TUKYSA/MOUNTAINEER in 2021, this year. Our late-stage programs, we plan to submit TV toward getting approval, enroll a newly opened study called innovaTV 301, which is a global confirmatory study to expand the label and get data for global approval of TV. Also working very hard with LV to try to initiate multiple pivotal trials. We have our early-stage pipeline. We intend to report data from many phase I programs. A notable one is SEA-CD40 for pancreatic cancer. We've treated a lot of patients, and we look forward to putting out the data there. Submitting a number of new INDs for novel product candidates, mainly focused on ADCs. With that, I will end and turn it back to Cory. Terrific. Thanks, Clay. We'll start with Q&A now. Again, a reminder, our audience can ask questions with the little blue button. We have a few in there. I want to start, though, by asking you about PADCEV and just kind of the evolution of the commercial dynamics you're seeing here, your kind of confidence that there's still ample room to grow in the relapse refractory marketplace. Sure. First of all, I'd like to introduce some of my executive colleagues. I have here Todd Simpson, our CFO. I have Chip Romp, who heads up our U.S. commercial team, and I have Roger Dansey, who's our Chief Medical Officer, on the call now. We could all answer questions. Your question is on PADCEV and future growth. As I mentioned in my remarks, we have two additional data sets being submitted this quarter, in the first quarter and second quarter, global or in the U.S. This is for expansion of the use of PADCEV in cohort two or in the randomized setting. Chip, can you talk a little about what you see with PADCEV out there in the world, what doctors think of it, and the expansion and growth that we continue have there, and with the current labels and the immediate future labels, not even counting the front line, which will be coming? Yeah. Thanks, Clay. Absolutely. PADCEV has been very well received by the medical community. It's represented an opportunity to fill a tremendous unmet medical need that existed in the marketplace. The metastatic urothelial market is a dynamic market. It is changing and evolving as we speak. We're looking forward to an opportunity to continue to move in closer proximity to frontline with regard to the adoption of maintenance therapy that we see now with the PD-1s taking place in the marketplace. We think there's some additional opportunity to reach and benefit a new subset of patients that we have not been able to get to due to our label requirements prior. To work in an investor question here on the subject. You say that cohort K will be fully enrolled by the end of 2021. Are you able to take an interim or a partially enrolled trial, or will you need to wait for sufficient follow-up on the full trial population? Yeah, that's more of a question for Roger. What are your thoughts on that, Roger? Sure. Cory, it's an interesting question. We haven't disclosed what our internal plans are with regard to analysis. What I can say to you, which is it's a very simple trial. It's two drugs put together, both of them highly active. The primary endpoint is overall response. Based on our experience so far with these two agents, we achieved that pretty quickly. In general, PADCEV, which works rapidly, produces responses very early on. We'll map to an early evaluation of ORR. The key piece for us is duration of response, because we need to have a meaningful amount of durability. Of course, we'll work on those plans in terms of timing, but those are the two data points that we need to take into account in terms of when we will be able to release data. Okay. A couple more quick PADCEV ones, and we'll move on to some of your other assets. Given that cohort K is PADCEV plus/minus KEYTRUDA in terms of its trial design, is it fair to look at this as something of a win-win setup? Cory, it's a really good question. We don't know how much in the frontline setting PADCEV does as a composition of its components. This is an important trial. My scientific part of me believes that the two drugs together will probably work better, but we don't know that for sure. We don't know how much KEYTRUDA adds to PADCEV. I think it'll be important globally, if the two together result in fantastic data and PADCEV alone is much lower, then it's an obvious thing. If PADCEV is the bulk of the response, then that might impact how we look at this from a global standpoint. It is a win-win in a sense. Roger, do you have anything you want to add to that? I think to repeat a little bit of what Clay is saying, two highly active agents. PADCEV is a remarkably active drug in bladder cancer. Put two active agents together with slightly different activity profiles. Bear in mind, the sort of hallmark of PD-1 inhibition is improvement in survival, without necessarily having very large impacts on things like response. It's understanding not only the initial response and the durability of the response, but other endpoints such as progression-free survival and overall survival are also important in evaluating the combination. I would say the data we've put out so far with that initial cohort with PADCEV and KEYTRUDA, the overall response rate is impressive, as is the duration of response, but so is the PFS and so is the OS. I think based on that data, one could assume or presume that the combination may in fact win out against the monotherapy. Obviously, we need to be driven by the data when we have it. Right. Okay. Last one for now on PADCEV is there seems to be some noise around rash. How much of an issue is this in the real world and in ongoing clinical trials? I'll start that, and Roger can chime in. First of all, we take patient safety very seriously. Nectin-4 is expressed on the skin. Rash is common. It's generally mild and reversible. We have seen some severe rashes. They're noted and described in our USPI. Overall, the risk-benefit of PADCEV has not materially changed since its approval about a year ago. Not only that, but we have newer data, even with EV-301, that has shown overall survival advantage. As we work with doctors and they work with patients, we do not believe that this is something that has an impact on us. Roger, do you want to comment further? Sure. As drugs get out into the marketplace and they get used more broadly, one can expect to see some things like this. Frankly, it's not surprising that people report rash. We know that rash is probably the dominant side effect of this drug, but it's manageable in the main. Some folks unfortunately get severe reactions. As Clay said, bladder cancer is a dread disease. The benefit risk really doesn't change whether one has specific terms associated with rash or just a generalized reporting of rash, which is currently in the label. Okay. An investor question on TUKYSA. Are you seeing adoption across several lines of HER2- positive breast cancer, or is it restricted to those with CNS involvement? Can you talk about other potential indications where TUKYSA may see additional approvals and/or data in 2021? Certainly, TUKYSA is used on patients with visceral and brain metastatic disease. It's not just one or the other, it's both. Chip, you could speak a little to that and talk about what you see and hear from docs on TUKYSA. Yeah, certainly. We're very pleased with where we're at with regard to the launch. It's been largely to plan. We had a significant uptake initially, and continue to see that. Doctors are very satisfied with the results that they're getting with TUKYSA. As Clay mentioned earlier, from the initial pivotal trial, worked in all the subsets, both in the primary and the secondary endpoints. We're seeing it both used in patients with and without brain metastasis. Okay. Can you comment on the accrual process in MOUNTAINEER? You said it should be done by the end of this year, time to data, for this product in colorectal. As soon as we have it done, you sort of have to follow duration. That's something that's depending on how we're looking at it, usually between six and 10 months, or six and 12 months duration that you want to follow it up because you want to have the best data and be able to inform doctors and patients with the right data. We're going to try to get this done as soon as possible. We're not looking to wait till the last day of the year. We're trying to get it done in 2021 this year and move forward. Our lead-in trial that we did on MOUNTAINEER was extraordinary. We had over 50% response rate, and if you may recall from ESMO that year, there were KOLs in the audience saying this should be adopted right away. It's something that we want to complete this study and go toward a pivotal submission and try to get it on the market. Okay. Another investor question on TUKYSA. Any updates of a potential combination with ENHERTU? Sure. Roger, do you want to take that? Yeah. We've actually initiated a trial, looking at the combination of TUKYSA plus ENHERTU. We think from a scientific and medical perspective, these are two highly active agents. They complement each other sort of from a mechanistic perspective. TUKYSA will severely suppress HER2 signaling inside the cell, ENHERTU will have both an outside effect by binding to HER2, and will also internalize and kill the cell. We think both drugs are active. It's important to study that combination, and we've initiated a trial. Okay. On ADCETRIS, I have another question here regarding the five-year ECHELON-1 updated ASH. Do you think you can gain market share in frontline Hodgkin lymphoma with these five-year PFS results? I think that they will be very helpful. Chip, do you want to give editorial comment on that? Sure. Absolutely. Five-year is an important benchmark for these patients. It's one that is referenced generally at the beginning of their diagnosis as important. We're excited to be able to, in the future, promote to this data. We do think it is meaningful. Okay. You guys are getting a lot of investor questions here. Another one is, should we expect to see data this year for PADCEV in tumors besides bladder? What are some of the other more important data cards to turn this year that can point to additional opportunities of some of your in-market assets or point to potential of early-stage assets? That's a big question because there's a lot of pieces. Basically, your key catalysts for the year. Yes. I think that with PADCEV, we have not given guidance yet on a basket study. That's certainly something that we're working on, and we're trying to see and evaluate whether Nectin-4 expression on other tumor types can be good and fair grounds to treat with PADCEV. That's something I've not given you guidance on yet. We want to have a substantive data set to not come out with a little bit of data and try to make hay out of that. We want to have real data, and we have built into the trial. We have expansion cohorts to look at data really closely. You'll see really strong data from us. The best thing I could tell you is it's not slowing down development at all. Presentations are just at certain time points with conferences, but we are developing PADCEV, whether it's in urothelial cancer or non-urothelial cancer, as best as we can to help as many patients as we can. When you look at catalysts, we have catalysts all across the board that I mentioned that would be coming out in my prepared remarks. With our main three drugs that are approved right now, we have 10 registrational trials, 10 across ADCETRIS, PADCEV, and TUKYSA. We have our EV-201 and EV-301 data that's coming out of ASCO GU, and then submissions on those, too. We have completing enrollment of cohort K, which is in the accelerated frontline, and the completing enrollment of TUKYSA MOUNTAINEER. Those are just the three assets. In our late-stage programs, we're going to be submitting TV and enrolling innovaTV 301 with TV and LV, trying to get that into pivotal studies this year with our new partner, Merck, whether it's single agent, combination with KEYTRUDA, or my preference, doing one of each, because the drug is very active and I think deserves to be tested in pivotal studies, single agent and combination. Stay tuned on that. That's another big thing this year. Our early-stage programs, we're going to be putting out lots of data from phase I, including from SEA-CD40 in pancreatic cancer, as well as some other agents, and starting two, three, four different new drugs this year. I mentioned a total of 14 drugs. We'll have more this year by the time the year is done. Okay. Terrific. Well, unfortunately, we're out of time. A lot more questions we could ask here, but I want to thank you all very much for joining us today and for the presentation and discussion. Thank you. Thank you. Thank you. Thanks, everyone.